Hereditary transthyretin amyloidosis (hATTR) is a rare inherited disorder that gets worse over time. It often affects the nerves, heart, liver, and kidneys, but it can also affect other organs.

HELIOS-B is a global, randomized, double-blind, placebo-controlled clinical trial that evaluated the efficacy and safety of AMVUTTRA (R) in adult patients with wtATTR or hATTR amyloidosis with ...

Alnylam Pharmaceuticals (NASDAQ:ALNY) said its medicine vutrisiran to treat polyneuropathy associated with hereditary transthyretin-mediated (hATTR) amyloidosis met all secondary goals at 18 months in ...

WASHINGTON – Angel says her family has been living with a rare disease they called “the curse” for generations. Known as hATTR Amyloidosis, the life-threatening condition was first accurately ...

Alnylam Announces New Data from ATTR Amyloidosis Programs at the Peripheral Nerve Society’s 2021 Annual Meeting − Phase 3b Open-Label Study Showed Treatment with Patisiran Achieved Rapid and Sustained ...

In a position statement published in Orphanet Journal of Rare Diseases, experts suggest that understanding the course of hereditary transthyretin-mediated amyloidosis (hATTR amyloidosis) can be best ...

(RTTNews) - RNAi therapeutics company Alnylam Pharmaceuticals, Inc. (ALNY) announced Tuesday that the European Commission has granted marketing authorization for AMVUTTRA (vutrisiran), an RNAi ...

The US Food and Drug Administration (FDA) has approved vutrisiran (Amvuttra, Alnylam Pharmaceuticals) for the treatment of polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis in ...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced that the Committee for Medicinal Products for Human Use (CHMP) ...

The investigational RNAi therapeutic vutrisiran (Alnylam Pharmaceuticals) met its primary and secondary endpoints in a phase 3 study of adults with hereditary transthyretin-mediated amyloidosis (hATTR ...

The U.S. Food and Drug Administration (FDA) approved Alnylam Pharmaceuticals’ ALNY lead drug candidate AMVUTTRA (Vutrisiran) for the treatment of the polyneuropathy of hereditary ...